Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7490754 | 0.88 | MAPT (0.54) | GFERSMN1; SMN2TSHRMAPTNPC1 | |
| SCHEMBL7490755 | 0.88 | MAPT (0.54) | GFERSMN1; SMN2TSHRMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL27434077 | 0.88 | GFER (0.45) | GFERSMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL7526146 | 0.85 | GFER (0.43) | GFERSMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL7526135 | 0.85 | GFER (0.43) | GFERSMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL1123684 | 0.84 | GFER (0.49) | GFERSMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL519257 | 0.83 | MAPT (0.56) | GFERSMN1; SMN2TSHRMAPTNPC1 | |
| SCHEMBL19384329 | 0.81 | MAPT (0.54) | MAPTNPC1RAB9AMAPK1L3MBTL1 | |
| SCHEMBL6710803 | 0.81 | MAPT (0.50) | GFERSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL21816341 | 0.78 | GAA (0.47) | GFERSMN1; SMN2TP53EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| EP-2284172-A1 | Immunomodulating heterocyclic compounds | MediGene Ltd. (GB) | 2011-02-16 | — | — | EP | disclosed |
| EP-2284172-A1 | Immunomodulating heterocyclic compounds | MediGene Ltd. (GB) | 2011-02-16 | — | — | EP | disclosed |
| EP-1603917-B1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | MEDIGENE LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| EP-1603917-B1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | MEDIGENE LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-5910495-A | TREATING RAPID GASTRIC EMPTYING IN NON-INSULIN DEPENDENT DIABETIC CONDITIONS; AGONIST ACTIVITY FOR CHOLECYSTOKININ-A RECEPTOR | GLAXO WELLCOME INC. (US) | 1999-06-08 | — | — | US | disclosed |
| US-5739129-A | AGONIST ACTIVITY | GLAXO WELLCOME INC. (US) | 1998-04-14 | — | — | US | disclosed |
| CN-1176646-A | CCK or gastrin modulating 5 -heterocyclic-1, 5-benzodiazepines | GLAXO WELLCOME INC (US) | 1998-03-18 | — | — | CN | disclosed |
| US-5646140-A | CHOLECYSTOKININ ANTAGONIST; APETITE CONTROL | GLAXO WELLCOME INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0756602-A1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC. (US) | 1997-02-05 | — | — | EP | disclosed |
| CN-1120843-A | Derivatives of class 1, 5-benzodiazepine * having CCK antagonistic or agonistic activity | GLAXO INC (US) | 1996-04-17 | — | — | CN | disclosed |
| EP-0694039-A1 | 1,5-BENZODIAZEPINE DERIVATIVES HAVING CCK ANTAGONISTIC OR AGONISTIC ACTIVITY | GLAXO WELLCOME INC. (US) | 1996-01-31 | — | — | EP | disclosed |
| WO-1995028419-A1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1994024149-A1 | 1,5-BENZODIAZEPINE DERIVATIVES HAVING CCK ANTAGONISTIC OR AGONISTIC ACTIVITY | GLAXO INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| US-4495351-A | FOR UROGENVITAL DISORDERS | VEB ARZNEIMITTELWERK DRESDEN (DD) | 1985-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | GFER 1223/4885SMN1; SMN2 4346/4885TP53 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.